Abbvie To Acquire Cerevel Therapeutics In Transformative Transaction To Strengthen Neuroscience Pipeline
Acquiring Company
AbbVie Inc.
Acquired Company
Cerevel Therapeutics
North ChicagoCambridgeManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaPharmaceutical ManufacturingDescription
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet needs remain for patients.
Quick answer
AbbVie Inc. is acquiring Cerevel Therapeutics, announced December 6, 2023. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Cerevel Therapeutics?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Cerevel Therapeutics based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Cerevel Therapeutics is based in Cambridge, Maryland, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abbvie To Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio (November 30, 2023)
- Lilly Completes Acquisition Of Point Biopharma (December 27, 2023)
- Astellas Completes Acquisition Of Propella Therapeutics (December 21, 2023)
- Astellas To Acquire Propella Therapeutics (November 15, 2023)
- United Therapeutics To Acquire Miromatrix Medical (October 30, 2023)
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition (January 18, 2024)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cerevel Therapeutics?
Cerevel Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on December 6, 2023. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Cerevel Therapeutics?
AbbVie Inc.'s acquisition of Cerevel Therapeutics was reported on December 6, 2023. AbbVie Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cerevel Therapeutics do?
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. It is privately held, operating in Pharmaceutical Manufacturing, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.